Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | RARA | P10276 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.45 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.45 |
| ▸ | CPS1 | P31327 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 2/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6767799 | 0.87 | MAOB (0.62) | MAOBMAOAPARP10PARP14CPS1 | |
| SCHEMBL2330110 | 0.87 | MCL1 (0.44) | MRGPRX4 | |
| SCHEMBL5838811 | 0.85 | ALDH1A1 (0.56) | — | |
| SCHEMBL13366264 | 0.83 | RARA (0.55) | MAOBRARARARBMAOACPS1 | |
| SCHEMBL18793210 | 0.81 | MAOB (0.51) | MAOBRARARARBMAOAPARP10 | |
| SCHEMBL1051747 | 0.81 | CPS1 (0.63) | CPS1 | |
| SCHEMBL7825340 | 0.81 | RARB (0.71) | MAOBRARARARB | |
| SCHEMBL8128200 | 0.81 | MAOB (0.44) | MAOBMAOAPARP10PARP14CPS1 | |
| SCHEMBL3874777 | 0.81 | RARA (0.63) | MAOBRARARARBMAOAMRGPRX4 | |
| SCHEMBL4279588 | 0.79 | MAOB (0.50) | MAOBRARARARBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710208-B2 | REACTING AN N-ALKYLATED POLYMERIC HYDROXAMIC ACID RESIN WITH AN ORGANOMETALLIC REAGENT TO LIBERATE THE KETONE | AVENTIS PHARMACEUTICALS INC. | 2004-03-23 | — | — | US | disclosed |
| US-20020183558-A1 | Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha, beta-unsaturated carboxylic acid and aldehyde compounds | AVENTIS PHARMACEUTICALS INC. | 2002-12-05 | — | — | US | disclosed |
| US-6392010-B1 | FLUOROPHENYL HYDROXYLAMINE RESIN | AVENTIS PHARMACEUTICALS INC. | 2002-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183558-A1 | Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha, beta-unsaturated carboxylic acid and aldehyde compounds | OGDH, OXGR1, ALDH7A1 | MAOB 317/4885RARA 125/4885RARB 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.